Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies

Summary The plasma concentration of adiponectin, an adipokine that has anti‐inflammatory, anti‐atherogenic and insulin sensitizing properties, is lower in obese subjects and could therefore be a target for therapy. In order to review and meta‐analyse prospective cohort studies investigating adiponec...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Obesity reviews Ročník 14; číslo 7; s. 555 - 567
Hlavní autori: Kanhai, D. A., Kranendonk, M. E., Uiterwaal, C. S. P. M., van der Graaf, Y., Kappelle, L. J., Visseren, F. L. J.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Blackwell Publishing Ltd 01.07.2013
Wiley Subscription Services, Inc
Predmet:
Adiponectin
Adiponectin - blood
Cardiovascular diseases
Cohort Studies
Coronary Disease - blood
Coronary Disease - epidemiology
coronary heart disease
Humans
Incidence
meta-analysis
Prospective Studies
Risk Assessment
Risk Factors
stroke
Stroke - blood
Stroke - epidemiology
Vascular diseases
ISSN:1467-7881, 1467-789X, 1467-789X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Summary The plasma concentration of adiponectin, an adipokine that has anti‐inflammatory, anti‐atherogenic and insulin sensitizing properties, is lower in obese subjects and could therefore be a target for therapy. In order to review and meta‐analyse prospective cohort studies investigating adiponectin concentration and the risk for incident coronary heart disease (CHD) or stroke, a systematic search of MEDLINE, EMBASE and Cochrane databases was performed. Two independent reviewers selected prospective cohort studies investigating the relationship between adiponectin level and incident CHD or stroke using ‘adiponectin’ and ‘cardiovascular disease’ or ‘stroke’ and their synonyms, excluding patients with clinically manifest vascular disease. Random‐effects models were used to calculate pooled relative risks (RRs) and 95% confidence intervals (95% CI). Generalized least squares regression was used to assess dose–response relationships for adiponectin concentrations from studies that provided RRs solely based upon categorical data regression. In total, 16 prospective cohort studies, comprising 23,919 patients and 6,870 CHD or stroke outcome events, were included in the meta‐analyses. An increase of 1 standard deviation in log‐transformed adiponectin did not lower the risk for CHD (RR 0.97; 95% CI 0.86–1.09). A 10 μg mL–1 increase in adiponectin conferred a RR of 0.91 (95% CI 0.80–1.03) for CHD and a RR 1.01 (95% CI 0.97–1.06) for stroke. In conclusion, plasma adiponectin is not related to the risk for incident CHD or stroke.
Bibliografia:ark:/67375/WNG-DBHTWR28-N
istex:406618E056F9EE976BEC84B92E34C86A141509F8
ArticleID:OBR12027
ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ISSN:1467-7881
1467-789X
1467-789X
DOI:10.1111/obr.12027